Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion.
Growth factors are important substances in the central control of wound healing during the exudative phase. Although these peptides have been applied frequently to chronic wounds in clinical studies, little is known about the naturally occurring levels at the wound site in correlation to healing in superficial wounds. We have therefore investigated the presence of these cytokines in partial thickness wounds. In 16 patients undergoing reconstructive surgery, split-thickness skin wounds were enclosed in cutaneous vinyl chambers filled with 2.5 ml of saline. Chambers placed over unwounded skin served as controls. After 24 hours, the accumulated wound fluid was harvested and replaced by 2.5 ml of saline until the wounds were healed. Wound fluid was centrifuged, aliquoted, and frozen at -70 degrees C. Samples were analyzed for protein and growth factors (insulin-like growth factor-1, epidermal growth factor, basic fibroblast growth factor, platelet-derived growth factor-AB, interleukin-1alpha, and transforming growth factor-beta1 and -beta2) and insulin-like growth factor-binding proteins 1 and 3 using a monoclonal Sandwich enzyme-linked immunosorbent assay and radioimmunoassay. All wounds healed in the liquid environment within 7 days (macroscopically) and 11 days (barrier function), respectively. In wound fluid, protein concentrations dropped from 5 mg/ml on day 1 to a baseline of 0.1 mg (unwounded skin), indicating a return of the barrier function. All growth factors could be measured already after 24 hours postwounding. However, the concentrations measured varied from 10 to more than 10,000 pg/ml between the different factors. The highest range was found for insulin-like growth factor-1 (21,000 to 41,000 pg/ml), the lowest for epidermal growth factor (3 to 63 and 3 to 88 pg/ml, respectively). Two different patterns of kinetics were distinguished: (1) a high initial peak decreasing to baseline values or below serum levels by the time of healing (insulin-like growth factor-1, insulin-like growth factor binding protein-1, -3, basic fibroblast growth factor, epidermal growth factor, platelet-derived growth factor-AB, transforming growth factor-beta1) and (2) a low initial concentration followed by an increase to a maximum at the time of epithelialization (interleukin-1alpha, transforming growth factor-beta2). Comparing the growth factor levels measured to serum baseline values, it was found that four of the growth factors appeared in wound fluid at above serum concentrations (interleukin-1alpha, transforming growth factor-beta2, basic fibroblast growth factor, epidermal growth factor); the other factors never reached serum values in wound fluid (insulin-like growth factor, transforming growth factor-beta1, platelet-derived growth factor-AB). It is concluded that the different profiles of secretion might reflect different functions of polypeptide growth factors such as stimulation of epithelialization (epidermal growth factor, insulin-like growth factor-1), matrix synthesis (transforming growth factor-beta), and inflammatory stimulation (interleukin-1alpha). The concentrations determined could serve as guidelines for adapted administration of growth factors once correlations to healing disorders such as overhealing and ulceration are established.
Vogt
P M
PM
Universitätsklinik für Plastische Chirurgie und Schwerbrandverletzte, Handchirurgiezentrum and Institut für Klinische Chemie und Laboratoriumsmedizin BG-Kliniken Bergmannsheil, Ruhr-Universität Bochum, Germany.
Lehnhardt
M
M
Wagner
D
D
Jansen
V
V
Krieg
M
M
Steinau
H U
HU
D000328:Adult; D016207:Cytokines / Q000032:analysis / Q000097:blood / Q000378:metabolism; D062109:Dermatologic Surgical Procedures; D004797:Enzyme-Linked Immunosorbent Assay; D004815:Epidermal Growth Factor / Q000032:analysis / Q000097:blood / Q000378:metabolism; D004848:Epithelium / Q000502:physiology; D005122:Exudates and Transudates / Q000737:chemistry / Q000378:metabolism; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000032:analysis / Q000097:blood / Q000378:metabolism; D006133:Growth Substances / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D006801:Humans; D007249:Inflammation; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000032:analysis / Q000378:metabolism; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000032:analysis / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000032:analysis / Q000378:metabolism; D007375:Interleukin-1 / Q000032:analysis / Q000097:blood / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010982:Platelet-Derived Growth Factor / Q000032:analysis / Q000378:metabolism; D011506:Proteins / Q000032:analysis / Q000378:metabolism; D019651:Plastic Surgery Procedures; D012867:Skin / Q000737:chemistry / Q000293:injuries* / Q000378:metabolism; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000097:blood / Q000378:metabolism; D014945:Wound Healing
D016207:Cytokines; D006133:Growth Substances; D018970:Insulin-Like Growth Factor Binding Protein 1; D018972:Insulin-Like Growth Factor Binding Protein 3; D007375:Interleukin-1; D010982:Platelet-Derived Growth Factor; D011506:Proteins; D016212:Transforming Growth Factor beta; C095477:platelet-derived growth factor AB; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D007334:Insulin-Like Growth Factor I